Skip to main content
Have a personal or library account? Click to login
The Burden and Trends of Degenerative Mitral Valve Disease at the Global, Regional, and National Levels From 1990 to 2021, With Projections to 2035 Cover

The Burden and Trends of Degenerative Mitral Valve Disease at the Global, Regional, and National Levels From 1990 to 2021, With Projections to 2035

Open Access
|Oct 2025

References

  1. Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease. Nature Reviews Cardiology. 2021;18(12):853864. DOI: 10.1038/s41569-021-00570-z
  2. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. Journal of the American College of Cardiology. 2020;76(25):29823021. DOI: 10.1016/j.jacc.2020.11.010
  3. Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: A compass for future health. Journal of the American College of Cardiology. 2022;80(25):23612371. DOI: 10.1016/j.jacc.2022.11.005
  4. Anyanwu AC, Adams DH. Etiologic classification of degenerative mitral valve disease: Barlow’s disease and fibroelastic deficiency. Seminars in Thoracic and Cardiovascular Surgery. 2007;19(2):9096. DOI: 10.1053/j.semtcvs.2007.04.002
  5. Basso C, Perazzolo Marra M. Mitral annulus disjunction: Emerging role of myocardial mechanical stretch in arrhythmogenesis. Journal of the American College of Cardiology. 2018;72(14):16101612. DOI: 10.1016/j.jacc.2018.07.069
  6. Sabbag A, Essayagh B, Barrera JDR, et al. EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC Council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed by the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society. Europace. 2022;24(12):19812003. DOI: 10.1093/europace/euac125
  7. van Wijngaarden AL, Kruithof BPT, Vinella T, et al. Characterization of degenerative mitral valve disease: Differences between fibroelastic deficiency and Barlow’s disease. Journal of Cardiovascular Development and Disease. 2021;8(2):23. DOI: 10.3390/jcdd8020023
  8. Abramowitz Y, Jilaihawi H, Chakravarty T, et al. Mitral annulus calcification. Journal of the American College of Cardiology. 2015;66(17):19341941. DOI: 10.1016/j.jacc.2015.08.872
  9. Fornes P, Heudes D, Fuzellier JF, et al. Correlation between clinical and histologic patterns of degenerative mitral valve insufficiency: A histomorphometric study of 130 excised segments. Cardiovascular Pathology. 1999;8(2):8192. DOI: 10.1016/S1054-8807(98)00021-0
  10. Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nature Reviews Cardiology. 2011;8(3):162172. DOI: 10.1038/nrcardio.2010.202
  11. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. European Heart Journal. 2003;24(13):12311243. DOI: 10.1016/S0195-668X(03)00201-X
  12. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnationallocations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440):21332161. DOI: 10.1016/S0140-6736(24)00757-8
  13. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440):21002132. DOI: 10.1016/S0140-6736(24)00367-2
  14. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet (London, England). 2024;403(10440):21622203. DOI: 10.1016/S0140-6736(24)00933-4
  15. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine. 2000;19(3):335351. DOI: 10.1002/(SICI)1097-0258(20000215)19:3<;335::AID-SIM336>3.3.CO;2-Q
  16. Das Gupta P. Standardization and decomposition of rates from cross-classified data. Genus. 1994;50(3–4):171196.
  17. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983;39(2):311324. DOI: 10.2307/2531004
  18. Møller B, Fekjaer H, Hakulinen T, et al. Prediction of cancer incidence in the Nordic countries: Empirical comparison of different approaches. Statistics in Medicine. 2003;22(17):27512766. DOI: 10.1002/sim.1481
  19. Jürgens V, Ess S, Cerny T, et al. A Bayesian generalized age-period-cohort power model for cancer projections. Statistics in Medicine. 2014;33(26):46274636. DOI: 10.1002/sim.6248
  20. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;63(22):24382488. DOI: 10.1016/j.jacc.2014.02.537
  21. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2017;70(2):252289. DOI: 10.1016/j.jacc.2017.03.011
  22. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021;77(4):450500. DOI: 10.1016/j.jacc.2020.11.035
  23. Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. The New England Journal of Medicine. 2023;388(22):20372048. DOI: 10.1056/NEJMoa2300213
  24. Makkar RR, Chikwe J, Chakravarty T, et al. Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA. 2023;329(20):17781788. DOI: 10.1001/jama.2023.7089
  25. Suri RM, Schaff HV, Dearani JA, et al. Survival advantage and improved durability of mitral repair for leaflet prolapse subsets in the current era. The Annals of Thoracic Surgery. 2006;82(3):819826. DOI: 10.1016/j.athoracsur.2006.03.091
  26. Mantovani F, Clavel MA, Michelena HI, et al. Comprehensive imaging in women with organic mitral regurgitation: Implications for clinical outcome. JACC Cardiovascular Imaging. 2016;9(4):388396. DOI: 10.1016/j.jcmg.2016.02.017
  27. Vakamudi S, Jellis C, Mick S, et al. Sex differences in the etiology of surgical mitral valve disease. Circulation. 2018;138(16):17491751. DOI: 10.1161/CIRCULATIONAHA.118.035789
  28. Kislitsina ON, Zareba KM, Bonow RO, et al. Is mitral valve disease treated differently in men and women? European Journal of Preventive Cardiology. 2019;26(13):14331443. DOI: 10.1177/2047487319833307
  29. Vassileva CM, McNeely C, Mishkel G, et al. Gender differences in long-term survival of Medicare beneficiaries undergoing mitral valve operations. The Annals of Thoracic Surgery. 2013;96(4):13671373. DOI: 10.1016/j.athoracsur.2013.04.055
  30. Elmariah S, Budoff MJ, Delaney JA, et al. Risk factors associated with the incidence and progression of mitral annulus calcification: The multi-ethnic study of atherosclerosis. American Heart Journal. 2013;166(5):904912. DOI: 10.1016/j.ahj.2013.08.015
  31. NCD Countdown 2030 Collaborators. NCD countdown 2030: Worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet (London, England). 2018;392(10152):10721088. DOI: 10.1016/S0140-6736(18)31992-5
  32. NCD Countdown 2030 Collaborators. NCD Countdown 2030: Efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries. Lancet (London, England). 2022;399(10331):12661278. DOI: 10.1016/S0140-6736(21)02347-3
DOI: https://doi.org/10.5334/gh.1489 | Journal eISSN: 2211-8179
Language: English
Submitted on: Feb 10, 2025
Accepted on: Oct 8, 2025
Published on: Oct 28, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Qiang Li, Yifan Yang, Zhi-Nan Lu, Xunan Guo, Xinmin Liu, Zhengming Jiang, Wenhui Wu, Chengqian Yin, Jianxin Li, Xiangfeng Lu, Guangyuan Song, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.